Cadrenal TherapeuticsCVKD
CVKD
About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Employees: 4
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
468% more capital invested
Capital invested by funds: $215K [Q4 2024] → $1.22M (+$1.01M) [Q1 2025]
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
60% more funds holding
Funds holding: 10 [Q4 2024] → 16 (+6) [Q1 2025]
2.85% more ownership
Funds ownership: 0.84% [Q4 2024] → 3.69% (+2.85%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$32
131%
upside
Avg. target
$32
131%
upside
High target
$32
131%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 131%upside $32 | Buy Reiterated | 16 May 2025 |
Financial journalist opinion
Neutral
Business Wire
3 days ago
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #cadrenaltherapeutics--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.
Neutral
Business Wire
1 week ago
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CKVD--Cadrenal Therapeutics will participate at this year's BIO International Convention 2025, taking place June 16-19, 2025 in Boston.
Neutral
Business Wire
1 month ago
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #ESKD--Cadrenal announces manufacturing and supply chain milestones for its lead drug, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant.
Neutral
Business Wire
1 month ago
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update.
Neutral
Business Wire
1 month ago
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics to present at inaugural Centri Capital Conference at Nasdaq on April 22, 2025.
Neutral
Business Wire
2 months ago
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
PONTE VEDRA, Fla.--(BUSINESS WIRE)-- #anticoagulation--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medi.
Neutral
Business Wire
3 months ago
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. “2024 for Cadrenal was a year of focus and laying the foundations for advancing tecarfarin into Phase 3 clinical develo.
Neutral
Business Wire
3 months ago
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE: ABT) to support Cadrenal's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Under the terms.
Neutral
Business Wire
4 months ago
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25 years of leadership in the cardiovascular f.
Neutral
Business Wire
4 months ago
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, leading with tecarfarin, a new Vitamin K antagonist will present at the 2025 BIO CEO & Investor Conference taking place at The New York Marriott Marquis on February 10-11, 2025. Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics, Inc., will present an overview of the company and updates on the.
Charts implemented using Lightweight Charts™